# US 2024/0392352 A1 · Method for transposase mediated spatial tagging and analyzing genomic dna in a biological sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392352 A1
- Document ID: US20240392352A1
- Status: Published application
- Kind: A1
- Application number: 18/800,689
- Filed: 2024-08-12
- Published: 2024-11-28
- Earliest claimed: 2021-01-29
- Assignees: 10x Genomics, Inc.
- Applicants: 10x Genomics, Inc.
- Inventors: Patrik Stahl; Maja Marklund; Enric Llorens Bobadilla; Jonas Frisen
- Web page: https://patentgrep.com/patent/US20240392352A1

## CPC

- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6841: In situ hybridisation
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to materials and methods for spatially analyzing nucleic acids fragmented with a transposase enzyme in a biological sample.

## Claims

### Claim 1

A method for determining genomic DNA accessibility, the method comprising:
(a) providing a biological sample on an array comprising a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises: (i) a spatial barcode and (ii) a capture domain;
(b) contacting the biological sample with a protease to degrade one or more histone proteins from the biological sample, thereby releasing accessible genomic DNA from the one or more histone proteins;
(c) contacting the biological sample with a transposome to insert a transposon end sequence into the released accessible genomic DNA, thereby generating fragmented genomic DNA;
(d) hybridizing the transposon end sequence of the fragmented genomic DNA to the capture probe;
(e) releasing one or more transposon end sequences of the fragmented genomic DNA not bound to the capture probe; and
(f) determining (i) a sequence of the spatial barcode or a complement thereof, and (ii) all or a portion of a sequence of the fragmented genomic DNA, or a complement thereof, and using the determined sequences of (i) and (ii) to determine genomic DNA accessibility in the biological sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protease is capable of degrading at least one linker histone protein and at least one core histone protein in the biological sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the protease is a serine protease, an aspartyl protease, a peptidase family Cl enzyme, a protease that is inhibited by the diazomethane inhibitor Z-Phe-Phe-CHN(2) or the epoxide inhibitor E-64, a lysosomal protease, a collagenase, or an azurophilic enzyme.

### Claim 4 (depends on 1)

The method of claim 1, wherein the protease is a collagenase.

### Claim 5 (depends on 1)

The method of claim 1, wherein the capture probe comprises a splint oligonucleotide, wherein the splint oligonucleotide is hybridized to the capture domain of the capture probe, and wherein in (d) the transposon end sequence of the fragmented genomic DNA hybridizes to the splint oligonucleotide.

### Claim 6 (depends on 5)

The method of claim 5, further comprising ligating the fragmented genomic DNA to the capture probe.

### Claim 7 (depends on 1)

The method of claim 1, wherein the capture probe comprises a cleavage domain, one or more functional domains, a unique molecular identifier, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hybridizing in (d) comprises hybridizing the transposon end sequence or a portion thereof to the capture domain or a portion thereof of capture probe.

### Claim 9 (depends on 1)

The method of claim 1, further comprising extending a 3′ end of the capture probe using the fragmented genomic DNA as a template.

### Claim 10 (depends on 9)

The method of claim 9, wherein the extending is performed using a DNA polymerase having strand displacement activity.

### Claim 11 (depends on 1)

The method of claim 1, further comprising performing a gap filling between the transposon end sequence and the fragmented genomic DNA.

### Claim 12 (depends on 1)

The method of claim 1, wherein the transposome comprises a Tn5 transposase enzyme, a Mu transposase enzyme, a Tn7 transposase enzyme, a Vibrio species transposase enzyme, or a functional derivative thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Tn5 transposase enzyme comprises a sequence that is at least 80% identical to SEQ ID NO: 1.

### Claim 14 (depends on 1)

The method of claim 1, wherein the determining in (f) comprises sequencing (i) the sequence of the spatial barcode or the complement thereof, and (ii) all or the portion of the sequence of the fragmented genomic DNA or the complement thereof.

### Claim 15 (depends on 1)

The method of claim 1, further comprising imaging and/or staining the biological sample.

### Claim 16 (depends on 1)

The method of claim 1, wherein the contacting the biological sample with the protease in (b) is for about 5 minutes to about 15 minutes.

### Claim 17 (depends on 1)

The method of claim 1, wherein the contacting the biological sample with the protease in (b) is at a temperature from about 30° C. to about 45° C.

### Claim 18 (depends on 1)

The method of claim 1, wherein the releasing in (e) comprises heating the biological sample.

### Claim 19 (depends on 18)

The method of claim 18, wherein the heating is to a temperature of about 65° C. to 85° C.

### Claim 20 (depends on 1)

The method of claim 1, wherein the biological sample is a tissue section.

### Claim 21 (depends on 20)

The method of claim 20, wherein the tissue section is a fresh, frozen tissue section, a fixed tissue section, a formalin-fixed paraffin-embedded fixed tissue section, an acetone fixed tissue section, a paraformaldehyde fixed tissue section, or a methanol fixed tissue section.

### Claim 22 (depends on 1)

The method of claim 1, wherein the providing the biological sample on the array in (a) comprises aligning the biological sample with the array.

### Claim 23 (depends on 1)

The method of claim 1, wherein contacting the biological sample with the transposome in (c) is performed under a chemical permeabilization condition, an enzymatic permeabilization condition, or both.

### Claim 24 (depends on 23)

The method of claim 23, wherein contacting the biological sample with the transposome in (c) is performed under a chemical permeabilization condition comprising a detergent selected from the group consisting of NP-40, Tween-20, Triton X-100, and Digitonin.

### Claim 25 (depends on 23)

The method of claim 23, wherein contacting the biological sample with the transposome is performed under an enzymatic permeabilization condition comprising a protease selected from the group consisting of a pepsin, a collagenase, and a Proteinase K.
